Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
Frequently asked questions
What sector does Seaport Therapeutics, Inc. Common Stock (SPTX) operate in?
Seaport Therapeutics, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Seaport Therapeutics, Inc. Common Stock (SPTX) current stock price?
As of the latest data, Seaport Therapeutics, Inc. Common Stock stock price is $20.83, with a previous close of $20.61. Seaport Therapeutics, Inc. Common Stock gained $0.22 in the last trading session, representing a 1.07% increase.
What is Seaport Therapeutics, Inc. Common Stock (SPTX) current market capitalization?
Seaport Therapeutics, Inc. Common Stock market cap is approximately 1.12 billion.
What is Seaport Therapeutics, Inc. Common Stock (SPTX) Earnings Per Share (EPS)?
The trailing EPS is -$2.48, and the forward EPS is -$2.57.
What is Seaport Therapeutics, Inc. Common Stock (SPTX) EBITDA?
Seaport Therapeutics, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -65.46 million.
Does Seaport Therapeutics, Inc. Common Stock (SPTX) pay dividends?
No. Seaport Therapeutics, Inc. Common Stock does not pay a dividend.
When is Seaport Therapeutics, Inc. Common Stock (SPTX) next earnings report?
Seaport Therapeutics, Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Seaport Therapeutics, Inc. Common Stock (SPTX) beta (volatility) score?
Seaport Therapeutics, Inc. Common Stock has a beta of 1195.546, indicating very high volatility compared to the market.
